𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Viremia Profiles in Hepatitis B Virus Carrier Children With Spontaneous e Antigen Seroconversion: A Case of Déjà Vu?

✍ Scribed by Chih–Lin Lin; Jia–Horng Kao

Book ID
119759975
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
140 KB
Volume
133
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A case-control study for early predictio
A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter
✍ Takahiro Yamaura; Eiji Tanaka; Akihiro Matsumoto; Akinori Rokuhara; Koji Orii; K 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract Factors influencing and predictive of seroconversion from hepatitis B e antigen (HBeAg) to antibody (anti‐HBe) were sought in a case‐control study of 61 patients with chronic hepatitis B who had been observed from 5 years before to 1 year after seroconversion, and 32 patients who did no

Shorter durations and lower doses of peg
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
✍ Y.-F. Liaw; J.-D. Jia; H.L.Y. Chan; K.H. Han; T. Tanwandee; W.L. Chuang; D.M. Ta 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 401 KB 👁 2 views

As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared. HBeAg-p